Sign Out
Ticagrelor is well tolerated in single doses up to 900 mg. Gastrointestinal toxicity was dose-limiting in a single ascending dose study. Other clinically meaningful adverse reactions which may occur with overdose include dyspnoea and ventricular pauses (see "Adverse Reactions").
In the event of an overdose, the previously mentioned potential adverse reactions could occur and ECG monitoring should be considered.
There is currently no known antidote to reverse the effects of ticagrelor, and ticagrelor is not dialysable (see "Pharmacology: Pharmacokinetics under Actions", "Precautions"). Treatment of overdose should follow local standard medical practice. The expected effect of excessive ticagrelor dosing is prolonged duration of bleeding risk associated with platelet inhibition. Platelet transfusion is unlikely to be of clinical benefit in patients with bleeding (see "Precautions"). If bleeding occurs, appropriate supportive measures should be taken.
